Ebos GroupASX:EBO +0.64%77 Shareholder Yield % is -2.91% as of Dec. 2025. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$32.93 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 113 Medical Distribution companies, Ebos Group ranks worse than 71.68% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Ebos Group's Shareholder Yield % was -2.91%.
Ebos Group (ASX:EBO) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Ebos Group Shareholder Yield % Related Terms
Ebos Group Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Ebos Group's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EBO vs MCK, CAH, COR: Shareholder Yield % Comparison
For the Medical Distribution subindustry, Ebos Group's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Shareholder Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Ebos Group's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Ebos Group (ASX:EBO) has a Shareholder Yield % of -2.91% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Ebos Group and its competitors. According to the industry distribution chart, Ebos Group ranks #81 out of 113 companies in the Medical Distribution industry, placing it in the top 71.7%.
Is Ebos Group's Shareholder Yield % too high?
Ebos Group's current Shareholder Yield % is -2.91%. Based on the distribution chart, Ebos Group ranks #81 out of 113 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Shareholder Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #81 out of 113 companies for Shareholder Yield %. This places Ebos Group in the lower half of its industry. The industry median Shareholder Yield % is 2.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Distribution company?
The median Shareholder Yield % among Medical Distribution companies is 2.36, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Shareholder Yield % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Shareholder Yield % is -2.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$32.93, compared to a current price of A$17.18 — trading 47.8% below its estimated fair value. The current Shareholder Yield % is -2.91%. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Shareholder Yield % is -2.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$17.18 is trading 47.8% below its estimated GF Value™ of A$32.93.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
Shareholder Yield %: -2.91%
GF Value™: A$32.93 vs. price of A$17.18 (47.8% below fair value)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score
Get the complete analysis for ASX:EBO
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
